Phase III
As 2018 comes to a close, analysts, journalists, investors and industry-watchers are studying their crystal balls to see what trends to watch in the upcoming year. Here are 7 trends most likely to be hitting the news cycle.
After a delay in review, the FDA approved Acorda’s Inbrija for the intermittent treatment of OFF episodes of Parkinson’s.
Met primary endpoint with robust statistical significance
Top-line data anticipated in the third quarter of 2019
Study will be conducted at up to 20 leading transplant centers in the U.S.
AstraZeneca released data from two clinical trials of roxadustat in anemia and of its trial of Lynparza in ovarian cancer. All the trials had positive results.
With the holiday upon us, many companies in the pharma and biotech industry have made some important announcements – some big, some small. BioSpace has gathered a number of announcements that might have gone unnoticed and put them together below.
EvaluatePharma and Vantage recently released their Vantage 2019 Preview which looks at the current year’s biopharma market and makes projections about the upcoming year.
Data Safety Monitoring Board (DSMB) recommended the continuation of RESOLVE-IT without any modifications, based on the pre-planned review of safety data, including adverse events and laboratory data
At 24 weeks, the study met its primary endpoint. Lilly’s Taltz demonstrated superiority against AbbVie’s Humira, the best-selling drug in the world, in improving the signs and symptoms of active PsA.
PRESS RELEASES